
Introduction Osteosarcoma is the most common primary malignant bone tumor; however, involvement of the temporal bone is exceptionally rare, particularly during pregnancy. The coexistence of malignancy and pregnancy presents unique diagnostic and therapeutic challenges requiring multidisciplinary management.
Neonatal acute liver failure is a rare, life-threatening condition. We present a 336/7-week-old neonate with severe coagulopathy and hyperbilirubinemia refractory to vitamin K1, plasma, and platelet transfusions. The mother had a history of two previous neonatal deaths, one of whom had similar coagulopathy. Gestational alloimmune liver disease (GALD) was strongly suspected following multidisciplinary review, although a definitive diagnosis could not be confirmed because of negative labial salivary gland iron staining and the decision to decline liver biopsy. Double-volume exchange transfusion on day 15 rapidly improved bilirubin and coagulation parameters, allowing discharge in stable condition. Mild recurrent cholestasis occurred after discharge. This case underscores that refractory coagulopathy and cholestasis unresponsive to conventional therapy, especially in the presence of a relevant family history, should raise suspicion for immune-mediated causes such as GALD. Exchange transfusion may be critical for improving outcomes.
Objective Maternal red cell alloimmunization is a rare pregnancy condition that can cause hemolytic disease of the fetus and newborn (HDFN), which can be serious and fatal. As subsequent alloimmunized pregnancies carry HDFN risk, families' future pregnancy decisions may be affected. Findings from qualitative interviews in alloimmunized mothers are presented to understand experiences and perspectives during their previous pregnancy affected by severe HDFN, aiming to inform patient-centered interventions. Study Design This article presents qualitative findings of a broader mixed-methods study published elsewhere. Semi-structured 1:1 interviews were conducted via Microsoft Teams with adults (≥18 years) who experienced a pregnancy within the past 5 years affected by severe HDFN (i.e., intrauterine transfusion, fetal loss after 14 weeks' gestation, or neonatal death within 4 weeks of birth due to HDFN). A patient advocacy group ensured study design's relevance, recruited participants, and helped interpret results. Interviews were audio-recorded, transcribed, and analyzed to identify key themes. Results Of 28 participants, 27 completed interviews. Participants reported a median 2 (range, 1-5) affected HDFN pregnancies and a median 4 (1-11) intrauterine transfusions during their most recent pregnancy affected by severe HDFN. Seven themes were identified: (1) diagnosis communication and information seeking, (2) emotional journey at diagnosis, (3) navigating the treatment regimen, (4) physical/emotional challenges during pregnancy, (5) impacts on social life, (6) experience at delivery, and (7) postdelivery adjustment and reflections. Results indicated that participants felt inadequately informed about their diagnosis, experienced significant emotional distress, along with difficulties managing intense monitoring/treatments. Many described their delivery as traumatic and their postpartum as very stressful, which influenced their decision about additional pregnancies. Conclusion These findings highlight opportunities to strengthen communication and support for pregnant individuals experiencing severe HDFN. Developing comprehensive support models and improving care, guided by patient preferences, could address the needs of affected individuals and families.
Objective Surgical necrotizing enterocolitis (NEC, Bell stage 3B) complicating neonatal supraventricular tachycardia (SVT) is exceedingly rare. We describe a novel per-rectal propranolol strategy to maintain antiarrhythmic prophylaxis during mandatory nil per oral (NPO) status imposed by NEC. Study Design This study includes a single case report at a tertiary neonatal unit in Western India. Results A 35-week neonate with antenatal fetal tachyarrhythmia (>300 beats per minute [bpm]) developed postnatal SVT at 6 h of life (280-300 bpm), requiring adenosine cardioversion and oral propranolol. On day of life (DOL) 4, hematochezia, abdominal distension, and portal venous gas indicated Bell stage 3A NEC, mandating NPO status. With enteral routes contraindicated, propranolol was continued per rectum, to our knowledge the first reported neonatal antiarrhythmic use of this route. Deterioration to pneumoperitoneum by DOL 8 necessitated laparotomy with jejuno-jejunal and ileo-caecal resection and anastomosis. No SVT recurred during NPO. The infant was discharged on DOL 25 on oral propranolol. Conclusion This first Indian report of SVT-associated surgical NEC highlights two novelties: Bell stage 3B NEC requiring surgery and per-rectal propranolol as a novel antiarrhythmic bridge during NPO. Clinicians should maintain vigilance for NEC in neonates with SVT regardless of hemodynamic stability, and consider the rectal route for propranolol when NPO.